GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Arcellx
Shares of Arcellx, a biotech company developing CAR-T therapy for cancer, are extremely volatile. Their price reflects not current revenue, but rather news about clinical trials and investor confidence in the potential of their breakthrough technology.
Share prices of companies in the market segment - Cancer blood
Arcellx is a biotech company focused on cell therapy for the treatment of blood cancers. We classify it as part of the Cancer Blood sector, and the chart below reflects the overall dynamics of this market segment, reflecting trends in this field of medicine.
Broad Market Index - GURU.Markets
Arcellx is a biotech company developing cutting-edge CAR-T cell therapy for the treatment of difficult-to-treat blood cancers such as multiple myeloma. As part of the GURU.Markets index, it reflects the hopes and risks of the biotech sector. The chart below represents the entire market. Compare Arcellx's performance to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ACLX - Daily change in the company's share price Arcellx
The daily volatility of Arcellx, a biotech company specializing in cancer cell therapy, reflects the sector's high risks and expectations. Change_co is an instant reaction to clinical trial news. This metric is essential for building risk models for innovative oncology companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Cancer blood
Arcellx, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with ACLX's performance, which depends on the results of its cell therapy clinical trials, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Arcellx is a biopharmaceutical company developing CAR-T cell therapy for cancer. The cell therapy sector is one of the most advanced and volatile in biotech. The chart below shows the average daily fluctuations in this industry, serving as a benchmark for evaluating the highly volatile Arcellx stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Arcellx
Arcellx is a biotech company working on cell therapy. Its shares are a bet on a scientific breakthrough. Their extreme volatility, driven by research data, is part of the dynamics of the innovation sector, which impacts the entire market.
Annual dynamics of market capitalization of the market segment - Cancer blood
Arcellx, Inc. is a clinical-stage biotech developing innovative CAR-T therapies for cancer treatment. Its stock performance is entirely dependent on clinical trial results and partnerships. The chart reflects the high risks and potential for breakthroughs in this cutting-edge field of oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Arcellx is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the key events are data releases, not macroeconomic statistics.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Arcellx
The value of Arcellx, a biotech company, is speculative. Monthly fluctuations on the chart reflect not operating cycles, but investor reactions to news of the clinical trials of its cell therapy for cancer, the success of which determines the company's entire future value.
Monthly dynamics of market capitalization of the market segment - Cancer blood
Arcellx is developing a new generation of CAR-T cell therapies to combat difficult-to-treat cancers. The company is at the forefront of biotechnology, where the stakes are high. The chart below reflects the pulse of the entire sector: ups and downs during periods of uncertainty, providing a backdrop for assessing Arcellx's risks and potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies working at the forefront of science often move independently of the market, reacting to clinical trial data. The chart below shows the overall sentiment. Is Arcellx living in a world of its own, where cell therapy news trumps overall market trends?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Arcellx
As a clinical-stage biotech, Arcellx exhibits high volatility. Weekly stock fluctuations are not a response to general market trends, but rather the result of news about trial progress, regulatory decisions, and scientific data publications. This chart shows the pulse of hope and risk in the biotech world.
Weekly dynamics of market capitalization of the market segment - Cancer blood
The cell therapy biotech sector, which includes Arcellx, is eagerly awaiting news of clinical trials. The success or failure of one player often influences sentiment across the entire industry. The chart below shows this overall pulse, allowing one to assess how disruptive Arcellx's technology is considered compared to its competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Arcellx is a clinical-stage biotech company developing cancer therapies. Its shares are caught up in news about trials and FDA decisions. The chart will show how its weekly performance is completely disconnected from overall market trends and driven solely by internal events.
Market capitalization of the company, segment and market as a whole
ACLX - Market capitalization of the company Arcellx
Arcellx's market capitalization chart is a financial proxy for hopes for a breakthrough in blood cancer treatment. Its high volatility reflects investor reactions to the results of clinical trials and the potential of its cell therapy. The scale of this indicator, even in its early stages, demonstrates the market's faith in the revolutionary potential of the treatments being developed by the company.
ACLX - Share of the company's market capitalization Arcellx within the market segment - Cancer blood
Arcellx is a biotech company at the forefront of the fight against blood cancer using CAR-T therapy. Its share of the market capitalization of its niche segment reflects investors' faith in its scientific platform. The chart shows how its share price changes as clinical trials progress and competition from pharma giants increases.
Market capitalization of the market segment - Cancer blood
Here's a chart showing the overall market capitalization of the biotech sector focused on blood cancer treatment. It's a multi-billion-dollar battleground for patients' lives. For Arcellx, which is developing cutting-edge CAR-T therapy, the chart's dynamics reflect investor optimism about breakthrough treatments and the potential market size for its drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Arcellx is developing cutting-edge treatments for blood cancer. Its market capitalization, though small on a global scale, represents enormous hope and the concentrated value of an intellectual breakthrough in medicine. It represents a share of the future victory over the disease in global capital.
Book value capitalization of the company, segment and market as a whole
ACLX - Book value capitalization of the company Arcellx
In biotech companies like Arcellx, book value reflects the material base for scientific breakthroughs. This includes the value of cutting-edge laboratories, patents, and high-tech equipment for developing cell therapies against cancer. Has the company increased its research and production assets to ensure future success? The chart below illustrates this dynamic.
ACLX - Share of the company's book capitalization Arcellx within the market segment - Cancer blood
Arcellx is fighting cancer, and its biotechnologies are backed by a significant infrastructure. These include not only patents but also state-of-the-art laboratories and pilot production lines for cell therapy development. The chart shows the company's share of the physical infrastructure necessary for developing cutting-edge treatments.
Market segment balance sheet capitalization - Cancer blood
Biotechnology is a knowledge-intensive industry, but as the asset chart shows, it also requires a significant capital base. Arcellx, which develops cell therapies, is investing in cutting-edge laboratories and preparing to build complex manufacturing facilities, making it capital-intensive.
Book value of all companies included in the broad market index - GURU.Markets
Arcellx fights cancer, but its foundation is quite tangible. The company's book value comes from its cutting-edge laboratories, cell therapy manufacturing facilities, and research and development equipment. The chart reflects the physical capital that underpins the creation of innovative, life-changing treatments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Arcellx
Arcellx's balance sheet consists of laboratories and capital. But the market sees more than that; it sees the potential for a breakthrough in cancer treatment. The ratio chart is a "hope indicator," showing how many times higher investors value the future success of its cell therapy than all of its current tangible assets. It's a pure bet on science and saving lives.
Market to book capitalization ratio in a market segment - Cancer blood
Arcellx is a biotech company developing cutting-edge treatments for blood cancer. Its value is based almost entirely on the potential of its scientific research and patents, rather than on its physical assets. This chart shows the enormous premium investors are paying for the hope of a future medical breakthrough.
Market to book capitalization ratio for the market as a whole
Arcellx develops cutting-edge cell therapies for cancer treatment. The company has virtually no tangible assets; its primary assets are its research and development, patents, and the promise of future treatments. This chart reflects the overall valuation, but how does the market attempt to value a biotech company on the cusp of a potential medical breakthrough?
Debts of the company, segment and market as a whole
ACLX - Company debts Arcellx
For clinical-stage biotech Arcellx, raising capital is a matter of life and death. The graph below shows how the company finances expensive and time-consuming research and development. This fuels innovation, potentially leading to breakthrough treatments for blood cancer.
Market segment debts - Cancer blood
Arcellx is a biotech company at the forefront of developing cell therapies for cancer treatment. Clinical trials require massive investments with uncertain outcomes. This chart illustrates how the company finances its research compared to other biotech players, where debt financing is often a measure of confidence in future drugs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Arcellx
Arcellx is a biotech company focused on developing cell therapies for cancer. This chart shows its financial structure. For companies in clinical development, which do not yet have stable revenue, the debt-to-equity ratio is critical. It reflects how Arcellx finances expensive research and development while awaiting approval of its drugs.
Market segment debt to market segment book capitalization - Cancer blood
Cancer-focused biotech companies like Arcellx incur significant expenditures on research and clinical trials. This chart shows how the sector as a whole finances its operations. It allows one to assess how Arcellx's financial model, which is still in drug development, compares to the overall debt policy of the biotech industry.
Debt to book value of all companies in the market
This chart is a barometer of the debt burden of the entire economy, including profitable corporations. Biotech companies like Arcellx, in the R&D stage, rely on investments rather than sales. A comparison with the overall market demonstrates how a financial model focused on scientific breakthroughs differs from traditional business and how it finances its future.
P/E of the company, segment and market as a whole
P/E - Arcellx
This chart for the biopharmaceutical company Arcellx illustrates how investors evaluate its future prospects, not current profits, which may never materialize. A very high value reflects hopes for successful clinical trials and the launch of breakthrough cancer drugs. This is a bet on future potential, but it comes with high risk.
P/E of the market segment - Cancer blood
Biotechnology, especially in the field of cancer cell therapy like Arcellx, is at the cutting edge of science. This chart shows the average valuation for commercially successful biotechs. It provides context, making it clear that Arcellx is not valued based on profits, but rather as a revolutionary platform whose potential investors compare to that of future industry leaders.
P/E of the market as a whole
Arcellx is a biotech company at the forefront of science, developing innovative cell therapies for the treatment of cancer and other serious diseases. This chart reflects the overall risk appetite of investors. For a company like ACLX, comparing its valuation to the market reveals whether its value is driven by general optimism about biotech or by faith in a breakthrough technology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Arcellx
Arcellx is a biotech company focused on developing cell therapies for the treatment of difficult-to-treat cancers, particularly multiple myeloma. This chart reflects investors' high expectations for the company's clinical trial success and potential drug approval. Its significance reflects a bet on scientific breakthroughs and the future commercialization of innovative treatments.
%20P%2FE%20Arcellx&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Arcellx&v=1772513565471 "Chart of the company's future (projected) P/E Arcellx")
Future (projected) P/E of the market segment - Cancer blood
Arcellx is at the forefront of the fight against cancer, developing innovative cell therapies. This chart provides investors with context by showing average profitability expectations in the sector. This allows them to assess how Arcellx's unique scientific developments compare to the revenue forecasts of other biotech companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772513565535 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
Arcellx is a biotech company developing cutting-edge treatments for blood cancer. Its value is determined not by current revenue, but by investors' faith in the success of clinical trials. Compared to the overall market valuations seen here, Arcellx is a story of a scientific breakthrough, where the potential of future drugs outweighs the current market situation.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513565594 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Arcellx
Arcellx is a biotech company focused on treating blood cancer. Its current financial picture is a balancing act between the enormous costs of clinical trials and potential future revenue from approved drugs. This graph likely reflects the capital burn in the race for breakthrough therapies, which is crucial to the company's survival.
Profit of companies in the market segment - Cancer blood
Arcellx is a biotech company at the forefront of the fight against cancer, developing innovative CAR-T cell therapies. Its future depends on successful clinical trials and drug approvals. This chart reflects the overall dynamics of the oncology sector, where treatment breakthroughs can lead to explosive growth and high profitability for the most successful players.
Overall market profit
Arcellx is developing cell therapy for blood cancer, making its success dependent on scientific breakthroughs and funding. However, even for biotech, the overall economic backdrop, shown in the chart, is important. During periods of growth, investors are more inclined to invest in risky but promising projects, providing Arcellx with capital.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Arcellx
Arcellx is a biotech company at the forefront of the fight against cancer, developing innovative cell therapies for the treatment of hematological malignancies. Its future depends on the success of clinical trials. This chart reflects analyst consensus estimates for future profitability, which are largely a bet on scientific breakthroughs.
%20profit%20of%20the%20company%20Arcellx&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Arcellx&v=1772513565748 "Graph of future (projected) profit of the company Arcellx")
Future (predicted) profit of companies in the market segment - Cancer blood
Arcellx is a biotech company focused on developing cell therapies for the treatment of cancer, specifically multiple myeloma. Its future depends on successful clinical trials and drug approvals. This chart shows profitability forecasts for the biotech sector, providing insight into the overall investment climate in the cancer treatment industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772513565763 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
Arcellx is a biotech company focused on developing cancer treatments. Its value and prospects are determined by clinical trial results, regulatory approvals, and scientific breakthroughs. The business operates by its own innovation calendar, largely uncorrelated with the general economic cycles that inform overall market profit forecasts.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513565848 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Arcellx
For Arcellx, a biotech company developing cancer drugs that doesn't yet have significant sales, this chart is a measure of hope. It shows how market value reflects not current revenues, but the enormous potential of its future drugs, assessing the likelihood of a breakthrough therapy.
P/S market segment - Cancer blood
Arcellx is a clinical-stage biotech company focused on developing innovative immunotherapies for the treatment of cancer and other hard-to-treat diseases. The chart reflects the average revenue estimate in the biotech sector, providing insight into how highly investors value the potential future revenue from Arcellx's breakthrough technologies.
P/S of the market as a whole
Arcellx is at the forefront of the fight against cancer, developing innovative cell therapies for the treatment of blood cancers. The company's revenue is still in its early stages and depends on the success of clinical trials. This chart provides an overview of market revenue estimates, which underscores the enormous expectations of the biotech company ACLX.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Arcellx
Arcellx is a biotechnology company focused on developing innovative cell therapies for the treatment of cancer, specifically multiple myeloma. This chart reflects investor expectations for future sales of its drugs. The company's valuation is entirely dependent on the success of clinical trials and the potential commercialization of its breakthrough treatments.
%20P%2FS%20Arcellx&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Arcellx&v=1772513566047 "The graph of the company's future (projected) P/S Arcellx")
Future (projected) P/S of the market segment - Cancer blood
Arcellx is a clinical-stage biotech developing advanced cell therapies (CAR-T) for the treatment of cancer and autoimmune diseases. Its valuation is based on the potential of its future drugs. This chart shows how the market values its future revenue if its developments are successful, compared to expectations for the biotech sector.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772513566049 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
Arcellx is a biotech company focused on developing cell therapies for the treatment of blood cancer. Its success depends on research results and future drug sales. This chart, while reflecting overall revenue expectations, also shows investors' risk appetite. During periods of optimism, investors are more willing to fund innovative but risky projects like Arcellx's, believing in a future breakthrough.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513566097 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Arcellx
Arcellx is a biotech company at the forefront of cancer research, developing innovative cell therapies, particularly for the treatment of multiple myeloma. As the company is in the development stage, its revenue may be volatile and dependent on partnerships and grants. This chart reflects the funding streams supporting its research.
Sales of companies in the market segment - Cancer blood
Arcellx is a biotech company focused on developing innovative immunotherapies for the treatment of cancer and other serious diseases. Its activities can be segmented by specific drugs or therapeutic platforms. This chart displays the financial flows associated with one of these areas, demonstrating its commercial or clinical progress.
Overall market sales
Arcellx is at the forefront of biotechnology, developing cell therapies for cancer treatment. Its success is not directly dependent on the short-term economic cycles shown in the chart. Instead, it is driven by scientific breakthroughs and investments in healthcare, which are creating a new knowledge and high-tech economy, transforming people's lives.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Arcellx
Arcellx is a clinical-stage biotechnology company developing innovative CAR-T therapy for the treatment of multiple myeloma and other cancers. Its future sales forecast is a market assessment of the likelihood of success in its clinical trials and the commercial potential of its cutting-edge cell therapy. This is a bet on a breakthrough in cancer treatment.
%20sales%20of%20the%20company%20Arcellx&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Arcellx&v=1772513566143 "Schedule of future (projected) sales of the company Arcellx")
Future (projected) sales of companies in the market segment - Cancer blood
Arcellx is a biotechnology company focused on developing cell therapies for cancer treatment. Its success depends on progress across the industry. This forecast reflects overall revenue expectations for the oncology biotechnology segment, allowing us to assess the growth potential analysts see in new treatments and how this impacts the investment climate in the sector.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772513566171 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
Arcellx, a cancer cell therapy company, is located in the innovative biotech sector. Its success depends on investment in healthcare. This chart of overall sales forecasts reflects the state of the economy, which impacts budgets and the healthcare system's readiness to implement expensive but cutting-edge treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513566222 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Arcellx
Arcellx is a biotech company focused on developing cell therapies for the treatment of blood cancers, specifically multiple myeloma. While in clinical trials, its financial performance reflects significant investment in R&D. This chart shows the current ratio of its enormous research expenditures to its as-yet-unrecognized commercial revenue.
Market segment marginality - Cancer blood
Arcellx is a biotech company at the forefront of cell therapy for cancer, particularly myeloma. Their high profitability in this sector is a result of breakthrough scientific developments and patent protection. This chart allows you to evaluate the potential operating efficiency of their innovative platform compared to other biopharmaceutical companies.
Market marginality as a whole
Arcellx is a biotech company developing cell therapies for the treatment of blood cancers. Its current valuation is based on the potential for future breakthroughs, not current revenue. This chart reflects the profitability of established businesses, while for ACLX, the key metrics are successful clinical trials and future cash flows from drug commercialization.
Employees in the company, segment and market as a whole
Number of employees in the company Arcellx
Arcellx is a biotech company pioneering cell therapy for cancer treatment. This chart visualizes the growth of its scientific and clinical potential. The team's growth reflects progress in developing innovative treatments and moving from research to late-stage clinical trials.
Share of the company's employees Arcellx within the market segment - Cancer blood
Arcellx is at the forefront of the fight against cancer, developing cell therapies. In biotech, scientific talent is the most important asset. This chart illustrates the company's size in the context of its highly specialized oncology workforce, highlighting its investment in human capital to create breakthrough treatments.
Number of employees in the market segment - Cancer blood
Arcellx is at the forefront of biotechnology, developing cell therapies for blood cancers. This chart reflects employment in the highly specialized field of oncology. The growing number of scientists and clinicians in this segment demonstrates active investment in research and development, creating a fertile environment for Arcellx's breakthrough technologies.
Number of employees in the market as a whole
Arcellx, a biotech company developing cancer therapies, operates in a sector less susceptible to economic cycles. However, a strong labor market, as illustrated by this chart, means better insurance coverage for patients and stable funding for the healthcare system, which is critical for the implementation and accessibility of innovative treatments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Arcellx (ACLX)
Arcellx is a biotech company developing cutting-edge cell therapy for cancer. The extremely high number on this chart reflects the market's valuation not of its plants, but of its intellectual capital. Investors are betting that a small team of brilliant scientists can create a drug worth billions of dollars, making each of them invaluable.
%20of%20the%20company%20Arcellx%20(ACLX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Arcellx-ACLX&v=1772513566547 "Chart of market capitalization per employee (in thousands of dollars) of the company Arcellx (ACLX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
Arcellx (ACLX) is a clinical-stage biotech company working on CAR-T therapy (a treatment for blood cancer). Its value comes from pure R&D and the hope of a future breakthrough. This chart shows the (speculative) market value the market attributes to each elite scientist, not its current operations.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772513566563 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
Arcellx is a biotech company developing innovative cell therapies for cancer treatment. Its entire value lies in its research and intellectual property. Success depends on a small group of scientists. This chart illustrates the enormous potential value the market places on the work of each researcher.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513566596 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Arcellx (ACLX)
Arcellx is a clinical-stage biotech focused on developing cell therapy (CAR-T) for cancer treatment. At this stage, the company may not yet be generating consistent profits. This chart (or lack thereof) shows how the company manages its R&D expenses per employee, primarily scientists. It reflects the "burn" of capital in pursuit of a future breakthrough or potential profitability.
%20Chart%20Arcellx%20(ACLX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Arcellx-ACLX&v=1772513566603 "Company Profit Per Employee (in thousands of dollars) Chart Arcellx (ACLX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
Arcellx is a clinical-stage biotech developing cutting-edge CAR-T therapy for cancer (myeloma). This chart shows the benchmark for "Cancer Blood." In this R&D sector, the benchmark is likely *negative*. Companies burn billions on R&D. Profit per scientist is a distant goal.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772513566609 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
Arcellx (ACLX) is a biopharmaceutical company developing next-generation cell therapy (CAR-T) for the treatment of cancer, specifically multiple myeloma. Their technology is focused on improving efficiency. This graph, showing average profit per employee, is important for biotech. It allows one to assess how much a sector where a handful of scientists can create a breakthrough drug outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513566618 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Arcellx (ACLX)
Arcellx is a biotech company at the forefront of the fight against cancer. In the early stages, its revenue per employee may be low or nonexistent. However, this graph will become crucial once its cell therapy reaches the market. It will demonstrate how a small team of scientists and managers can generate massive revenue from the sale of a life-saving drug.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Arcellx-ACLX&v=1772513566639 "Sales chart per company employee Arcellx (ACLX)")
Sales per employee in the market segment - Cancer blood
Arcellx is a clinical-stage biopharmaceutical company focused on CAR-T therapy for cancer and autoimmune diseases. This chart shows revenue per employee. For a company without stable sales (during ongoing research), this metric may be low, but its comparison to the segment demonstrates how the company is managing resources on the path to commercialization.
Sales per employee for the market as a whole
Arcellx is a biotech company at the forefront of developing CAR-T therapies for cancer, particularly multiple myeloma. In the early stages of development (before drug approval), revenue for such companies is often zero or comes from partnerships. This graph is critical: it shows the point at which R&D begins to convert into commercial revenue or reflects the effectiveness of partnerships per scientist.
Short shares by company, segment and market as a whole
Shares shorted by company Arcellx (ACLX)
Arcellx is a biotech company developing CAR-T cell therapy for the treatment of blood cancers, specifically myeloma. This is one of the hottest areas in medicine. However, investors also see risks: intense competition, high development costs, and the binary outcome of clinical trials. This chart shows the number of those betting on trial failure.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Arcellx-ACLX&v=1772513566701 "Short Shares Chart for the Company Arcellx (ACLX)")
Shares shorted by market segment - Cancer blood
Arcellx is a biopharmaceutical company focused on developing CAR-T therapy for the treatment of cancer, specifically multiple myeloma. This is at the cutting edge of science, but the biotech sector is highly risky. This chart shows the overall bets against the industry, reflecting investor skepticism about the success of clinical trials or future commercialization.
Shares shorted by the overall market
Arcellx (ACLX) is a clinical-stage biotech (CAR-T). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives ACLX of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Arcellx (ACLX)
Arcellx is a clinical-stage biotech company working in cancer cell therapy. Its shares are extremely sensitive to trial news. This chart for ACLX can soar above 70 on positive R&D data. The <30 zone often reflects research failures or general risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Arcellx-ACLX&v=1772513566767 "RSI 14 indicator chart for the company's stock Arcellx (ACLX)")
RSI 14 Market Segment - Cancer blood
Arcellx (ACLX) is the "next wave" in cancer treatment. It's a biotech company developing CAR-T therapy to fight blood cancer (multiple myeloma). It's a high-risk bet. This chart shows the overall sentiment in the biotech sector. It helps us understand: is ACLX overheated by expectations for R&D, or is this a general overheating of the oncology biotech sector as a whole?
RSI 14 for the overall market
Arcellx (ACLX), a biotech company working on blood cancer treatments, relies heavily on this chart. Its survival depends on "research cash." During periods of market euphoria, investors are willing to fund risky but promising developments. During periods of panic, the cash flow is shut off, and companies like ACLX can face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ACLX (Arcellx)
Arcellx is a clinical-stage biotech focused on developing CAR-T cell therapy for cancer, specifically multiple myeloma. For companies of this type, analyst opinions are crucial. This chart shows their consensus forecast, which is based almost entirely on clinical trial results, market size estimates, and potential FDA approval timelines.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ACLX-Arcellx&v=1772513566957 "A chart showing analyst consensus forecasts for the expected stock price. ACLX (Arcellx)")
The difference between the consensus estimate and the actual stock price ACLX (Arcellx)
Arcellx (ACLX) is a biotech company developing a new generation of CAR-T cell therapy for difficult-to-treat cancers such as myeloma. This chart shows analyst expectations. It measures the gap between the price and the consensus target, reflecting the potential (or risk) for success in their clinical trials.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ACLX-Arcellx&v=1772513566972 "A chart showing the difference between the consensus forecast and the actual stock price. ACLX (Arcellx)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
Arcellx is a biotech company at the forefront of medicine. It is developing a new generation of CAR-T therapy for the treatment of difficult-to-treat blood cancers, such as multiple myeloma. This chart shows analysts' overall expectations across the biotech sector, reflecting whether experts believe breakthroughs in oncology are possible.
Analysts' consensus forecast for the overall market share price
Arcellx is a clinical-stage biotech focused on developing CAR-T therapy for blood cancers, specifically multiple myeloma. This chart shows the overall market risk appetite. For Arcellx, as a company whose value is based entirely on future expectations (trial success), overall market optimism is critical for raising the capital needed for expensive research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Arcellx
Arcellx is a biotech company at the forefront of cell therapy. They are developing a new generation of CAR-T therapies for the treatment of difficult-to-treat blood cancers, such as multiple myeloma. Their signature feature is a novel binding technology that promises greater efficacy. This chart is an assessment of their scientific platform. It reflects investor expectations for clinical data and the potential of their lead candidates.
AKIMA Market Segment Index - Cancer blood
Arcellx is a next-generation biotech focused on cell therapy (CAR-T) for the treatment of blood cancer (myeloma). Their unique technology (spartX) promises to make CAR-T safer and more effective. This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does Arcellx's breakthrough R&D platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Arcellx is a biotech company focused on developing CAR-T therapy (a treatment for blood cancer). It's a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story, driven by trial news, compares to the broader economic trends that influence investor risk appetite.
